This inventor holds 4 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Glaxosmithkline Intellectual Property Development Limited, Chroma Therapeutics Limited. Active years: 2014-2017.
Company Filing History:
3 out of 242 
1 out of 19 Years Active: 2014-2017
Title: Francesca Ann Day: Innovator in HDAC Inhibitors
Introduction
Francesca Ann Day is a prominent inventor based in Abingdon, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of HDAC inhibitors. With a total of 4 patents to her name, her work has the potential to impact the treatment of various diseases.
Latest Patents
Francesca's latest patents include innovative compounds that inhibit HDAC activity. One of her notable inventions involves compounds of formula (I) that demonstrate efficacy in treating lymphoma and rheumatoid arthritis. These compounds are characterized by specific structural elements, including A, B, and D, which can independently represent either carbon or nitrogen. Additionally, the compounds feature a divalent radical and various functional groups that enhance their therapeutic potential.
Career Highlights
Throughout her career, Francesca has worked with esteemed organizations such as GlaxoSmithKline Intellectual Property Development Limited and Chroma Therapeutics Limited. Her experience in these companies has allowed her to refine her expertise in drug development and patenting processes.
Collaborations
Francesca has collaborated with notable professionals in her field, including Alan Hornsby Davidson and David Charles Festus Moffat. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Francesca Ann Day is a trailblazer in the realm of HDAC inhibitors, with a strong portfolio of patents that reflect her innovative spirit. Her contributions to pharmaceutical research continue to pave the way for new treatment options.